Compare Stocks: TCRT, NXTC, UNCY, and BOLT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$5.96 +0.8%	$4.58	$3.10 ▼ $7.78	$11.51M	0.85	92,375 shs	8,689 shs
NXTC NextCure	$6.18 -0.9%	$6.01	$1.55 ▼ $15.74	$28.21M	1.22	664,689 shs	5,350 shs
TCRT Alaunos Therapeutics	$1.60 -1.5%	$1.64	$0.72 ▼ $4.50	$5.28M	-1.02	2.22 million shs	19,856 shs
UNCY Unicycive Therapeutics	$3.59 -1.4%	$4.23	$3.33 ▼ $8.74	$99.95M	1.91	941,282 shs	261,553 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	-5.59%	-7.37%	+38.08%	+76.42%	+26.01%
NXTC NextCure	+4.18%	+21.68%	-0.80%	-24.12%	-32.94%
TCRT Alaunos Therapeutics	+0.62%	-11.96%	-46.53%	-16.06%	-45.82%
UNCY Unicycive Therapeutics	-3.70%	+4.60%	-2.41%	-33.94%	-29.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$5.96 +0.8%	$4.58	$3.10 ▼ $7.78	$11.51M	0.85	92,375 shs	8,689 shs
NXTC NextCure	$6.18 -0.9%	$6.01	$1.55 ▼ $15.74	$28.21M	1.22	664,689 shs	5,350 shs
TCRT Alaunos Therapeutics	$1.60 -1.5%	$1.64	$0.72 ▼ $4.50	$5.28M	-1.02	2.22 million shs	19,856 shs
UNCY Unicycive Therapeutics	$3.59 -1.4%	$4.23	$3.33 ▼ $8.74	$99.95M	1.91	941,282 shs	261,553 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	-5.59%	-7.37%	+38.08%	+76.42%	+26.01%
NXTC NextCure	+4.18%	+21.68%	-0.80%	-24.12%	-32.94%
TCRT Alaunos Therapeutics	+0.62%	-11.96%	-46.53%	-16.06%	-45.82%
UNCY Unicycive Therapeutics	-3.70%	+4.60%	-2.41%	-33.94%	-29.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.25	Hold	$14.50	143.49% Upside
NXTC NextCure	2.00	Hold	$20.00	223.78% Upside
TCRT Alaunos Therapeutics	2.00	Hold	N/A	N/A
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.25	408.36% Upside

Current Analyst Ratings Breakdown

Latest TCRT, NXTC, UNCY, and BOLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/13/2026	TCRT Alaunos Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
11/10/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/15/2026	BOLT Bolt Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/8/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/29/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$15.00 ➝ $13.00
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$4.70M	2.44	N/A	N/A	$13.81 per share	0.43
NXTC NextCure	N/A	N/A	N/A	N/A	$1.20 per share	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A
UNCY Unicycive Therapeutics	$680K	147.03	N/A	N/A	$1.41 per share	2.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$33.38M	-$16.44	N/A	N/A	N/A	-611.47%	-126.23%	-54.70%	N/A
NXTC NextCure	-$55.84M	-$6.77	N/A	N/A	N/A	N/A	-191.33%	-125.95%	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-232.60%	-158.99%	11/17/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	2.49	N/A	N/A	-91.50%	-61.47%	N/A

Latest TCRT, NXTC, UNCY, and BOLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/17/2026	Q3 2026	TCRT Alaunos Therapeutics	-$15.75	N/A	N/A	N/A	N/A	N/A
11/12/2026	Q3 2026	BOLT Bolt Biotherapeutics	-$3.68	-$2.25	+$1.43	-$2.25	$0.45 million	N/A
11/10/2026	Q3 2026	NXTC NextCure	-$0.90	-$1.29	-$0.39	-$1.29	N/A	N/A
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	6.05%	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	1.47	2.61	2.61
NXTC NextCure	N/A	2.31	3.47
TCRT Alaunos Therapeutics	N/A	0.77	0.77
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
NXTC NextCure	42.65%
TCRT Alaunos Therapeutics	27.72%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	9.40%
NXTC NextCure	11.90%
TCRT Alaunos Therapeutics	16.14%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	23	1.93 million	1.75 million	Not Optionable
NXTC NextCure	40	4.58 million	4.03 million	No Data
TCRT Alaunos Therapeutics	1	3.31 million	2.78 million	No Data
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Optionable

TCRT, NXTC, UNCY, and BOLT Headlines

Recent News About These Companies

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

November 10 at 2:41 AM | americanbankingnews.com

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026 | insidermonkey.com

Unicycive Therapeutics (UNCY) Projected to Release Quarterly Earnings on Wednesday

November 4, 2026 | marketbeat.com

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026 | globenewswire.com

Unicycive Therapeutics consensus price target decreased by 10.97% to $28.97

November 2, 2026 | msn.com

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

November 2, 2026 | businesswire.com

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

November 2, 2026 | globenewswire.com

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

November 2, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

November 2, 2026 | globenewswire.com

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact ...

October 31, 2026 | reflector.comR

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 31, 2026 | newsfilecorp.comN

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

October 31, 2026 | globenewswire.com

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

October 31, 2026 | seekingalpha.com

UNCY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 30, 2026 | newsfilecorp.comN

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026

October 29, 2026 | newsfilecorp.comN

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

October 29, 2026 | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 29, 2026 | globenewswire.com

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), Papa John's International, Inc. (PZZA), and FuelCell Energy, Inc. (FCEL): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

October 28, 2026 | globenewswire.com

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

October 28, 2026 | prnewswire.com

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 28, 2026 | newsfilecorp.comN

UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

October 28, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, NXTC, UNCY, and BOLT Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$5.96 +0.05 (+0.76%)

As of 12:15 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

NextCure NASDAQ:NXTC

$6.18 -0.05 (-0.85%)

As of 12:18 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Alaunos Therapeutics NASDAQ:TCRT

$1.60 -0.03 (-1.54%)

As of 12:17 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Unicycive Therapeutics NASDAQ:UNCY

$3.59 -0.05 (-1.37%)

As of 12:18 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, NXTC, UNCY, and BOLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, NXTC, UNCY, and BOLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, NXTC, UNCY, and BOLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, NXTC, UNCY, and BOLT Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

NextCure NASDAQ:NXTC

Alaunos Therapeutics NASDAQ:TCRT

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, NXTC, UNCY, and BOLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, NXTC, UNCY, and BOLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, NXTC, UNCY, and BOLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, NXTC, UNCY, and BOLT Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

NextCure NASDAQ:NXTC

Alaunos Therapeutics NASDAQ:TCRT

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools